In Search of the Holy Grail: Evidence of Amyloid Fibril Regression in ATTR Cardiac Amyloidosis
- PMID: 33129738
- PMCID: PMC8543316
- DOI: 10.1016/j.jcmg.2020.08.021
In Search of the Holy Grail: Evidence of Amyloid Fibril Regression in ATTR Cardiac Amyloidosis
Keywords: ATTR; amyloidosis; cardiac magnetic resonance imaging.
Conflict of interest statement
Author Disclosures Dr. Ruberg has received research support from National Institutes of Health (R01HL139671), Akcea Therapeutics, Eidos Therapeutics, and Pfizer. Dr. Siddiqi has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression.JACC Cardiovasc Imaging. 2021 Jan;14(1):189-199. doi: 10.1016/j.jcmg.2020.07.043. Epub 2020 Oct 28. JACC Cardiovasc Imaging. 2021. PMID: 33129740
References
-
- Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016;387:2641–54. - PubMed
-
- Kristen AV, Brokbals E. Aus dem Siepen F, et al. Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis. J Am Coll Cardiol 2016;68:13–24. - PubMed
-
- Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol 2020;17:413–26. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
